期刊论文详细信息
| Is the duration of adjuvant trastuzumab debate still clinically relevant? | |
| Editorial Material | |
| 关键词: HER2-POSITIVE BREAST-CANCER; PLUS TRASTUZUMAB; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER; COMBINATION; PERTUZUMAB; SAFETY; WOMEN; | |
| DOI : 10.1016/S0140-6736(19)30946-8 | |
| 来源: SCIE | |
【 授权许可】
Free